China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more crowded with the looming entry of generics.
The drug, ecnoglutide, is approved for chronic weight management in overweight or obese adults, Pfizer announced Friday via WeChat. The company secured China rights to the therapy from local startup Hangzhou Sciwind Bioscience Co. in a $495 million deal in late February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.